Mitchell, P. & Moyle, J. Evidence distinguishing between chemical and chemosmotic mechanisms of electron transfer phosphorylation. Nature 208 1205-1206 (1965).
Morais, R. et al. Ability to form tumor in animated nude mice of human cell lines lacking mitochondrial DNA. Cancer Res . 54 3889–3896 (1
Cavalli, L. R., Varella-Garcia, M. & Liang, B. C. Reduced tumorigenic phenotype after depletion of mitochondrial DNA. Cell Growth Difference . 8 1189–1198 (1997).
Madar, I. et al. Absorption characteristics of the novel PET compound 18F-fluorobenzyl triphenyl phosphonium in canine myocardium. J. Nucl. Med . 47 1359–1366 (2006).
Weinberg, F. et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl Acad. Sci. United States 107 8788–8793 (2010).
Ji, H. et al. LKB1 modulates the differentiation and metastasis of lung cancer. Nature 448 807–810 (2007).
Shackelford, D. B. et al. Inactivation of LKB1 dictates the therapeutic response to the non-small cell lung cancer drug phenformin metabolism. Cancer cell 23 143–158 (2013).
Madar, I. et al. Characterization of the membrane potential uptake of the new PET tracer 18F-fluorobenzyl triphenylphosphonium cation. Eur. J. Nucl. Med. Mol. Imaging 34 2057–2065 (2007).
Smith, R. A., Hartley, R. S., and Murphy, Targeting MP Mitochondria Therapeutic Agents and Probes. Antioxid. Redox signal . 15 3021–3038 (2011).
Kim, D. Y. et al. Evaluation of a mitochondrial voltage sensor, (18F-fluoropentyl) triphenylphosphonium cation in a rat model of myocardial infarction. J. Nucl. Med . 53 1779–1785 (2012).
Madar, I. et al. Detection and quantification of the evolution of apoptosis evolution using the PET voltage sensor 18 F-fluorobenzyl triphenyl phosphonium. J. Nucl. Med . 50 774–780 (2009).
Logan, A. et al. Evaluation of the potential of the mitochondrial membrane in cells and in vivo using targeted chemistry of click and mass spectrometry. Cell Metab . 23 379–385 (2016).
Waldmann, C. M. et al. Automated multidose synthesis of potentiometric PET probe 4 – [ 18 F] fluorobenzyl-triphenylphosphonium ([ 18 F] FBnTP). Mol. Imaging Biol . 20 205–212 (2017).
Dykens, J. A. et al. Biguanide-induced mitochondrial dysfunction leads to increased lactate production and cytotoxicity of aerobically positioned HepG2 cells and human hepatocytes in vitro . Toxicol. Appl. Pharmacol . 233 203–210 (2008).
Li, F. et al. Inactivation of LKB1 induces a redox imbalance to modulate non-small cell lung cancer and therapeutic response. Cancer Cell 27 698–711 (2015).
Giordano, S., Lee, J., Darley-Usmar, VM & Zhang, J. Distinctive effects of rotenone, 1-methyl-4-phenylpyridinium and 6-hydroxidopamine on cellular bioenergy and cell death. PLoS One 7 e44610 (2012).
Singer, T. P. & Ramsay, R. R. Reaction sites of rotenone and ubiquinone with mitochondrial NADH dehydrogenase. Biochim. Biophys. Acta 1187 198–202 (1994).
Caboni, P. et al. Rotenone, degelin, their metabolites, and the rat model of Parkinson's disease. Chem. Really. Toxicol . 17 1540–1548 (2004).
Bridges, HR, Jones, AJ, Pollak, MN & Hirst, J. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria, Biochem. J . 462 475–487 (2014).
Owen, MR, Doran, E. and Halestrap, AP Evidence that metformin exerts its anti-diabetic effects by inhibiting mitochondrial respiratory chain complex 1. Biochem. J . 348 607–614 (2000).
Wheaton, W. W. et al. Metformin inhibits the mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife 3 e02242 (2014).
Sanchez-Rangel, E. & Inzucchi, S. E. Metformin: clinical use in type 2 diabetes. Diabetologia 60 1586–1593 (2017).
Birsoy, K. et al. Metabolic determinants of cancer cell sensitivity to glucose restriction and biguanides. Nature 508 108–112 (2014).
Hensley, C. T. et al. Metabolic heterogeneity in human lung tumors. Cell 164 681–694 (2016).
de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes determines the evolution of lung cancer. Science 346 251–256 (2014).
Momcilovic, M. et al. The GSK3 signaling axis regulates the adaptive metabolism of glutamine in squamous cell carcinoma of the lung. Cancer Cell 33 905-921.e905 (2018).
Momchilovich, M. et al. Increasing energy stress selectively targets LKB1-deficient small cell lung cancer. Cancer Res . 75 4910–4922 (2015).
Su, CY, Chang, Y.C., Yang, C.J., Huang, M.S. & Hsiao, M. The reverse prognostic effect of NDUFS1 and NDUFS8 in lung cancer reflects the oncoanuscular role of mitochondrial complex I. Sci. Rep . 6 31357 (2016).
Molina, J. R. et al. The oxidative phosphorylation inhibitor exploits the vulnerability of cancer. Nat. Med . 24 1036-1046 (2018).
Wittig, I., Braun, H. P. & Schägger, H. Blue native PAGE. Nat. Protocols 1 418–428 (2006).